A corrole nanobiologic crosses the blood-brain-barrier and recognizes triple negative breast cancer: Implications for targeting brain metastases

Creators: Medina-Kauwe, L.; Sims, J.; Taguiam, M.; Hanson, C.; Alonso-Valenteen, F.; Cui, X. Tracy; Wagner, S.; Sorasaenee, K.; Moats, R.; Marban, E.; Chung, A.; Gray, H. B.; Gross, Z.; Giuliano, A.

Abstract

Patients with breast cancer metastases to the brain on average survive less than one year. These tumors tend to be resistant to current therapies, and the majority of targeted therapeutics are unable to breach the blood brain barrier (BBB) to reach these tumors, thus improved alternatives are urgently needed.

Additional Information

Additional details

Views

Downloads

	All versions	This version
Views	0	0
Downloads	0	0
Data volume	0 Bytes	0 Bytes

More info on how stats are collected....

Resource type: Journal Article
Publisher: American Association for Cancer Research
Published in: Cancer Research, 76(S4), Art. No. P6-17, ISSN: 0008-5472.
Conference: 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2015

Created:: August 20, 2023
Modified:: October 18, 2023